HOWARD MAYER, Pfizer Global Research, New London CT MARK WAINBERG, McGill University, Montreal Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angele
HOWARD MAYER, Pfizer Global Research, New London CTMARK WAINBERG, McGill University, Montreal
Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007In a population of treatment-experienced HIV-infected subjects, maraviroc plus optimised background antiretroviral therapy provided significantly superior virologic control and increases in CD4 cell counts compared with placebo plus optimized background therapy. There were no clinically relevant differences in the safety profiles between the maraviroc and the placebo treatment groups. These drugs do not attack the virus itself but rather block host cells’ CCR5 cell surface cytokine receptors that HIV interacts with to gain entry into the cell. At the Los Angeles conference Dan Keller heard about the studies fromHoward MayerandMark Wainberg.
Related Episodes
Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability
Peter Tyrer REFERENCE: Lancet 371:57 January 5, 2008 PETER TYRER, Imperial College, W6 8RP London A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients
New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
Terry Gernsheimer TERRY GERNSHEIMER, University of Washington Medical Center, Seattle An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chroni
Which HIV Treatment is Best for Patients with HIV and Hepatitis C?
Juan Berenguer REFERENCE: Abstract V-1385, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JUAN BERENGUER, Hospital Gregorio Marañón, Madrid A ret